Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Miraka HD: Sales Up 11.2% with Addition of New Subsidiaries
June 27, 2011
- Nycomed Takes Over Bisphosphonate from Roche
June 27, 2011
- Takeda to Start PIII Trial for Hib Vaccine
June 27, 2011
- Eiken: Sales Up 2.7% Driven by Extraordinary Demand due to Disaster
June 27, 2011
- NanoCarrier to Obtain Substance Patent for pH-Responsive Micelles
June 27, 2011
- Otsuka to Start PI for Cancer Vaccine OCV-105 in Japan
June 27, 2011
- Takara Bio: Sales Down 3.0% due to Decline in Sales of Scientific Instruments
June 27, 2011
- Call For “Copayment Revision”Remains Unchanged in Revised SS Reform Plan
June 27, 2011
- NCC, Shimadzu Tie Up to Develop Advanced Cancer Treatment Technology
June 27, 2011
- Takeda Sues 18 Generic Companies for Actos Patent Infringement
June 27, 2011
- Compassionate Use of Unapproved Drugs to Require Clarification of Roles, Responsibilities
June 27, 2011
- Sangi Develops Oral Formulation for Cisplatin
June 27, 2011
- Taiyo's Acquisition by Teva Provides New Opportunity for GE Ind.: Mr Honda of Mylan
June 27, 2011
- FDA Issues Warning on Bladder Cancer Risk Associated with Actos
June 27, 2011
- Pfizer to Conduct First-ever “Virtual Clinical Trial”
June 27, 2011
- Do Practice and Experience Maketh the Marketer?
June 27, 2011
- Korosho to Promptly Assess Bladder Cancer Risk due to Actos
June 27, 2011
- Dacogen Increases OS in AML Patients: Eisai
June 27, 2011
- Aratani Family Excluded from Teva-Controlled Taiyo
June 27, 2011
- Novartis, Ono to Promote Rivastigmine Stressing Its Beneficial Effects on ADL
June 27, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…